Understanding Post Exertional Malaise (PEM) in ME/CFS
Post-exertional malaise (PEM) is a defining symptom of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), marked by a significant worsening of symptoms or the development of flu-like symptoms following physical or mental exertion. PEM can be triggered by even minimal activity and lead to severe and prolonged debilitation. https://m.youtube.com/watch?time_continue=2&v=VHTztUKsGn8&embeds_referring_euri=https%3A%2F%2Fwww.omf.ngo%2F&embeds_referring_origin=https%3A%2F%2Fwww.omf.ngo&source_ve_path=MjM4NTE Key Characteristics of Post-Exertional Malaise PEM manifests as […]
The Life Improvement Trial
The Life Improvement Trial (LIFT) Study AIM The Life Improvement Trial (LIFT) aims to investigate two drugs, separately and in combination, Pyridostigmine (commonly known as Mestinon) and Low-Dose Naltrexone (LDN), for efficacy and to research the difference between responders and non-responders. LEAD INVESTIGATORS David Systrom, MD Jonas Bergquist, MD/PhD Donna Felsenstein, MD Wenzhong Xiao, PhD […]
Studying CSF to further reveal pathogenesis mechanisms in ME/CFS
The goal of this research is to reveal more information about the role of immunology and neuroinflammation in ME/CFS, and the underlying mechanisms of related pathogenesis that takes place.
Multi-Omic Approaches to Solve Post-Acute COVID-19 (MOSAIC)
The purpose of this study is to facilitate early detection of ME/CFS in people with Long COVID and better understand disease progression.
OMF Australia Team
OMF Australia, led by Rebecca Morse, is driving research excellence in post-infection diseases through global collaboration.
Annual Reports
Annual Report and Audited Financial Statements 2023 Report 2022 Report 2021 Report
Financial Information
Audited Financial Statements 2022 Annual Report & Financial Statements 2021 Annual Report & Financial Statements
General Practitioner Recruitment
General Practitioner Recruitment ME/CFS andLong COVID Myalgic Encephalomyeltis / Chronic Fatigue Syndrome (ME/CFS) is a multisystem, chronic and complex disease (msCCD) that, pre-COVID, affected around 230,000 Australians[1]. In 2020, the direct medical cost was estimated at $5.295b, or $23,022 per case per year, and the aggregate community cost at $14.5b per year[2]. Recent studies indicate […]
BOSS-ME: Biological Outlier and
Subtyping Software for ME/CFS
This project will develop a software tool to rapidly look for metabolism anomalies in an individual which might be explained by their genes. It will also look for potentially damaging genes in individuals and it will attempt to group ME/CFS patients based on their genetic and metabolic profiles.
Itaconate Trap Study
This project aims to look at metabolic traps in central carbon metabolism that lead to observed altered energy production pathways in ME/CFS.
